{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-021381","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.346557+00:00","generated_at":"2026-06-02T09:32:52.604757+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aadi Bioscience Q1 FYARRO sales $5.4M; PRECISION1 fully enrolled; net loss $18.3M","bullets":["FYARRO net sales $5.4M, down 8.8% YoY due to distributor ordering and fewer patient initiations.","Net loss $18.3M vs $15.2M in Q1 2023; cash $88.3M expected to fund operations into Q4 2025.","PRECISION1 trial fully enrolled; two-thirds interim analysis expected Q3 2024, full data early 2025.","Terminated Mirati/BMS collaboration for adagrasib combo; prioritizing Phase 2 trials in EEC and NETs.","Management expects return to sales growth in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-021381","json":"https://secwatch.observer/filing/0001628280-24-021381.json","markdown":"https://secwatch.observer/filing/0001628280-24-021381.md","text":"https://secwatch.observer/filing/0001628280-24-021381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000162828024021381/0001628280-24-021381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000162828024021381/aadi-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:32:52.604757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f24d7ddc643b5d6c44c1087fa7e962e8fffd56a8","claim":"Whitehawk Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $5.4 million, net income $18.3 million.","evidence_excerpt":"for the First Quarter 2024 and Provides Corporate Update Fully enrolled registration-intended PRECISION1 trial; two-thirds interim analysis planned for Q3 2024 FYARRO® sales of $5.4 million for Q1 2024, reflects distributor ordering patterns and fewer commercial patient initiations at the start of the year Conference call to be held today at 8:30 am EDT LOS ANGELES,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000162828024021381/0001628280-24-021381-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$5.4 million"},{"label":"Net income","value":"$18.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}